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Karenia brevis, formerly Gymnodinium breve, a
brevetoxin-producing dinoﬂagellate, is recog-
nized as the major harmful algae forming the
red tide blooms in the Gulf of Mexico (Davis
1948). Two classes of brevetoxins were origi-
nally isolated from K. brevis by high pressure
liquid chromatography (Risk et al. 1979).
Structural analysis of these fractions identiﬁed
two backbone structures, containing either 11
(brevetoxin-B) or 10 (brevetoxin-A) fused
cyclic ether rings (Lin et al. 1981; Shimizu
et al. 1986). Each backbone structure has sim-
ilar functional groups and is subject to similar
metabolic modiﬁcations (Wang et al. 2004).
Brevetoxins bind to voltage-gated sodium
channels to alter gating transitions interfering
with the sensitive movements that transition
the channel’s closed, open, and inactivated
states (Catterall and Risk 1981). The initial
actions of brevetoxins lead to nerve activation;
within a few seconds of nerve activation, tran-
sient repetitive neuronal discharges are fol-
lowed by action potential depression and
eventually by a complete blockade of neuronal
excitability (Huang et al. 1984). 
The direct consumption of brevetoxin-
laden shellfish causes the food poisoning
referred to as neurotoxic shellfish poisoning
(NSP) in humans (McFarren et al. 1965).
NSP has become a rare phenomenon, even
with the frequent occurrence of red tide events,
in large part due to effective monitoring and
management of shellfish harvest. However,
inhalation of airborne brevetoxins at beaches
remains common, and the occupational and
recreational hazards have been the subject of
recent investigations (Backer et al. 2003,
2005). Experimental exposure of brevetoxin
aerosols was ﬁrst demonstrated by Woodcock
(1948), and in the last decade several studies
have characterized the toxicokinetics and
adverse effects of brevetoxins after intratracheal
exposure of rats or sheep (Abraham et al. 2005;
Benson et al. 1999). During this time, various
animal and tissue explant models have been
used to discriminate the molecular actions of
brevetoxins on voltage-gated sodium channels
in lung smooth muscle, autonomic nerve, and
central respiratory centers (Ramsdell 2008).
Exposure to brevetoxin-containing aerosols has
also been shown to cause severe allergic reac-
tions in asthmatic patients (Fleming et al.
2007; Kirkpatrick et al. 2006), but to date the
adverse effects of direct exposure to the respira-
tory tract have not been found to be severe in
healthy subjects.
A second potentially adverse mode of
brevetoxin action may be oxidative damage as
result of brevetoxin metabolism. Previous
research has shown that the brevetoxin B
(PbTx-2) is widely metabolized after systemic
administration to rats, after exposure to
freshly isolated rat hepatocytes, and after treat-
ment with cDNA-expressed rat cytochrome
P-450 enzymes (Radwan and Ramsdell 2006;
Radwan et al. 2005). Metabolic reactions were
observed on the A-ring, H-ring, and R-group
of the terminal K-ring. They included 
hydrolysis (A-ring), epoxidation (H-ring),
oxidation (R-group aldehyde), reduction
(R-group aldehyde and α, β-unsaturated
carbon), and peptide conjugation (R-group
α,β-unsaturated aldehyde) (Figure 1). The
epoxide metabolites are of interest because
epoxides are highly reactive intermediates that
react with nucleophilic sites to form covalent
adducts with cellular macromolecules such as
DNA and proteins (Koskinen and Plna 2000).
The large variability of phase I or II
enzymes among animal species and their tar-
get organs deﬁnes a key question concerning
organ-speciﬁc toxicity. Whether the actual tar-
get has the capacity to activate (or efﬁciently
deactivate) chemicals is a key factor in suscep-
tibility to toxin adduction. Lung is a target
organ for the toxicity of most inhaled toxins.
Occupational, accidental, or prolonged pul-
monary exposure to elevated concentrations of
brevetoxins is now the primary route for toxic-
ity in humans during red tide blooms. Yet the
mechanism by which lung cells metabolize
brevetoxin to reduce its potential toxicity is
still unknown. Results of several studies indi-
cate that a variety of xenobiotic-metabolizing
cytochromes [such as cytochrome P450
(CYP) 1A and CYP3A families] in the human
lung and in lung-derived cell lines contributes
to the in situ activation of pulmonary toxins
(Castell et al. 2005). Lung cells also express
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BACKGROUND: Human exposure to brevetoxins produced by the red tide organism, Karenia brevis,
is an increasing public health concern. Using in vitro exposure of rat liver cells to brevetoxin B
(PbTx-2), the primary toxin product of K. brevis, we previously showed that it formed C27,28-epoxy
brevetoxin metabolites capable of covalently binding to nucleic acids, a common initiation step for
carcinogenesis.
OBJECTIVE: This study was undertaken to evaluate nucleic acid adduction in lung following in vitro
and in vivo brevetoxin exposures.
METHODS: To clarify reactions of brevetoxin epoxide with DNA, we analyzed reaction products of
PbTx-6 (a C27,28 epoxide metabolite of brevetoxin B) with nucleosides. We also analyzed adducts
from nucleic acid hydrolysates of isolated rat lung cells treated with PbTx-2 or PbTx-6 in vitro and
lung tissue from rats after intratracheal exposure to PbTx-2 or PbTx-6 at 45 µg toxin/kg body
weight. 
RESULTS: Our results indicate that PbTx-2 forms DNA adducts with cytidine after treatment of iso-
lated lung cells, and forms DNA adducts with adenosine and guanosine after intratracheal exposure.
CONCLUSIONS: These results are consistent with metabolic activation of highly reactive brevetoxin
intermediates that bind to nucleic acid. These ﬁndings provide a basis for monitoring exposure and
assessing the hazard associated with depurination of brevetoxin–nucleotide adducts in lung tissue.
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http://dx.doi.org/ [Online 24 March 2008]phase II enzymes such as epoxide hydrolase,
UGT1A (glucuronyl transferase), and GST-
P1 (glutathione S-transferase), which largely
act as detoxifying enzymes.
Adduct formation is a key step in inducing
genotoxicity as a result of exposure to chemi-
cals and metabolites that damage nucleic acid.
The present study aimed to investigate breve-
toxin adduction with nucleic materials in the
lungs of exposed rats and thus to provide
insight into DNA adduction by brevetoxins
following metabolic activation. Detection of
brevetoxin–nucleic acid adduction has phar-
macological and risk assessment importance
and should provide a foundation for biological
monitoring of human exposure to such geno-
toxic environmental agents.
Materials and Methods
Materials. Brevetoxins PbTx-2 (MH+, m/z
895) and PbTx-6 (MH+, m/z 911), derived
from K. brevis cultures [purity reported by ven-
dor to be ≥ 95% by high performance liquid
chromatography (HPLC)], were purchased
from EMD Chemicals, Inc. (San Diego, CA,
USA). Nucleosides guanosine and cytosine
were purchased from Calbiochem (EMD
Biosciences, Inc., San Diego, CA, USA). Total
nucleic acid was isolated using DNeasy Tissue
Kit produced by Qiagen Inc. (Germantown,
MD, USA). Dulbecco’s modified Eagle
medium (DMEM) was purchased from
Invitrogen (Carlsbad, CA, USA). Rat lung cells
(CCL-192/RFL-6) were purchased from the
American Type Culture Collection (Manassas,
VA, USA). All other analytical or molecular
biologic grade chemicals used in this study
were purchased from either Sigma Chemical
Co. (St. Louis, MO, USA) or Fisher Scientiﬁc
(Suwanee, GA, USA).
Semisynthesis of nucleoside adducts with
PbTx-6. Reaction mixtures (200 µL total vol-
ume) of PbTx-6 (200 µM) were incubated
with aliquots of 50 mM equivalents of individ-
ual nucleosides prepared in 100 mM phos-
phate buffer at pH 7.4. The incubation was
carried out in a shaking bath overnight at
37°C. The reaction mixture was centrifuged at
900 × g for 5 min to remove any particulates.
We isolated the brevetoxin nucleoside adducts
in the supernatant using a 500 mg C-18 car-
tridge (Varian; Palo Alto, CA, USA) previously
conditioned with 3 mL methanol followed by
3 mL distilled water. Reactions were loaded,
washed with 3 mL 10% methanol, and
adducts were eluted with 5 mL 85% methanol.
We dried and reconstituted adducts in 50%
methanol for further radioimmunoassay (RIA)
and HPLC/mass spectrometry (MS) analyses.
In vitro treatment of lung cells with
PbTx-2 and PbTx-6. We prepared toxins in
methanol and diluted them in the culture
medium (DMEM) so that the ﬁnal methanol
concentration was 1.5% (vol/vol); we then
preincubated the preparation at 37°C for
10 min. Aliquots of rat lung cell culture sus-
pension were transferred into new incubation
wells and preincubated at 37°C for 10 min.
We initiated toxin exposure by adding
PbTx-2– or PbTx-6–enriched medium to a
well containing cells. The final incubation
mixture contained 35 µM of toxin and a cell
count of approximately 1.1 × 106 cells/mL.
Control reactions were preformed by incubat-
ing cells in brevetoxin-free medium. We
determined cell viability (> 86%) before expo-
sure using the trypan blue (0.4%) exclusion
test. All incubations were performed at 37°C
for 18 hr in a 5% CO2 humidified atmos-
phere. Cells were pelleted by centrifugation at
1,500 × g for 10 min and immediately frozen
at –80°C for further nucleic acid extraction.
Rat intratracheal exposures to PbTx-2 and
PbTx-6. Brevetoxin treatments were carried out
at Charles River Laboratories Inc., (Horsham,
PA, USA) using 12-week-old Charles River
male rats [Crl:CD(SD)IGS BR VAF/Plus;
225–250 g body weight]. Animals were sepa-
rated into three groups of ﬁve rats per group
and identified using Monel self-piercing ear
tags. Brevetoxins dissolved in 10% methanol
were further diluted in physiological saline con-
taining 0.01% Emulphor EL-620 (GAF Corp.,
New York, NY, USA). Rats in the treatment
groups were administered PbTx-2 (group 1) or
PbTx-6 (group 2) at 45 µg/kg body weight
through intratracheal instillation. We deter-
mined the dosage by a preliminary range-ﬁnd-
ing study of the maximally tolerable dose for
PbTx-2 as defined by labored breathing not
greater than 30 min after exposure. Brieﬂy, rats
were anesthetized using 5% isoﬂurane in O2
and intubated intratracheally as described previ-
ously (Medinsky et al. 1986). The doses, in a
volume of 0.15 mL saline, were instantaneously
delivered directly to the lung by a Luer-Lok
syringe through a 16-gauge catheter. Rats were
killed 24 hr after treatment, and the lungs were
collected immediately and kept frozen at –80°C
until use. Control rats received brevetoxin-free
vehicle solution (group 3). Animal use was con-
ducted according to Good Laboratory Practice
Procedures, and the animals were treated
humanely and with regard for alleviation of suf-
fering. The experimental protocol was approved
by the Charles River Laboratories Institutional
Animal Care and Use Committee.
Nucleic acid extraction and digestion. We
isolated nucleic acid from rat lung using
Qiagen Genomic-tips, essentially as described
by the manufacturer, with the following mod-
ifications. Cultured cells (~ 3.3 × 106/test)
were thawed and resuspended in 200 µL
phosphate buffer (0.1 M). Lung tissues were
minced into smaller pieces in a Petri dish con-
taining Dulbecco’s phosphate-buffered saline
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Figure 1. Schematic diagram showing the intermediary metabolites generated after in vitro metabolic
bioactivation pathways of brevetoxin-B in rat liver cells.
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CH3(PBS) and 20 mM EDTA, pH 7.8, on ice.
We transferred 25-mg pieces to a 1.5-mL cen-
trifuge tube and rinsed them at least three
times in PBS. Cells or lung tissues were ini-
tially digested with protease K for 4 hr at
65°C. The mixture was loaded into the
DNeasy spin column placed in a 2-mL collec-
tion tube. Unbound substances were collected
during washing process. We determined the
purity of the eluted nucleic acid extract by the
ratio of absorbance at 260 nm (A260) and
A280 (the accepted purity ratios A260/A280
were ~ 1.85). We determined the concentra-
tion based on a solution containing 50 µg/mL
of double-stranded DNA having an
absorbency (optical density; OD) of 1.0 at a
wavelength of 260. Extracts were stored at
–80°C until use.
Nucleic acid hydrolysis and adduct puriﬁ-
cation. Extracts were acid hydrolyzed in 0.1 N
HCl at 75°C for 30 min (Hertzog et al.
1980). We then adjusted the pH to about 4.5
with 5 N NH4OH. The nucleic acid hydro-
lysates were redissolved in 10% methanol and
loaded onto a previously conditioned SPE
C-18 cartridge (500 mg; Varian). The car-
tridge was washed with 5 mL distilled water,
and brevetoxin adducts were then eluted with
10 mL 85% methanol. The eluate containing
brevetoxin nucleoside adducts was concen-
trated to dryness under nitrogen stream. We
resuspended the dried adducts in 100 µL of
Radwan and Ramsdell
932 VOLUME 116 | NUMBER 7 | July 2008 • Environmental Health Perspectives
Figure 3. LC/MS analysis of semisynthesized brevetoxin nucleic acid adducts. Rel Int, relative intensity. (A) Extracted ion current (m/z 860–1,400) from total ion
chromatograms for brevetoxin–cytidine, brevetoxin–guanosine, and unbound PbTx-6. (B–D) Extracted total ion chromatogram, mass spectra , and product for
brevetoxin–cytidine (B), brevetoxin–guanosine (C), and unbound PbTx-6 (D). The brevetoxin-adduct fragment patterns shown in (B) and (C) depict a hypothetical
nucleoside linkage to the epoxide to illustrate potential nucleoside fragmentation. 
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Figure 2. RIA of brevetoxin activity recovered from
reaction products of PbTx-6 (mean ± SD) in the
absence (Cont PbTx-6) and presence of guanosine
(PbTx–Guanosine) or cytidine (PbTx–Cytodine).
Incubation of PbTx-6 with individual nucleoside was
carried out at 37°C for 18 hr, and brevetoxin prod-
ucts were separated using a C-18 cartridge. 
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RIA. We performed an RIA selective for
toxins with the B-type backbone brevetoxin as
described previously (Woofter et al. 2003).
Tests were carried out in borosilicate glass
tubes using antibodies raised in sheep immu-
nized with PbTx-2–fetuin conjugate
(Garthwaite et al. 2001). Assays were con-
ducted in RIA buffer, a PBS containing
0.01% Emulphor-EL 620 with a ﬁnal volume
of 500 µL/test. Brieﬂy, 5 µL of adduct extract,
or PbTx-3 (the PbTx-2 terminal alcohol
reduction product) standard set (from 0.01 to
1,000 nM) was incubated with 20 µL anti-
PbTx antiserum (1:4,000) in RIA buffer for
1 hr at 25°C. Thereafter, 0.4 nM of the
3H-PbTx-3 tracer was added, and the incu-
bation proceeded for another hour. Finally, we
added 100 µL Sac-Cel (IDS Diagnostics,
Fountain Hills, AZ, USA) to each of the assay
tubes allowing the separation of the bound
and unbound brevetoxin. The Sac-Cel mix-
ture was ﬁltered onto 25-mm diameter GF/B
glass fiber filters (Whatman, Newton, MA,
USA). The filters were immersed in 5 mL
Scinti-verse (Fisher, Suwannee, GA, USA) for
18 hr, and the radioactivity was counted on a
Tri-Carb 3100TR liquid scintillation counter
(Packard Bioscience Company, Meriden, CT,
USA). Standard curves were constructed for
each individual experiment, and results were
expressed as PbTx-3 equivalents per micro-
gram DNA in the original extract. Extracts
from controls did not have measurable matrix
interference. The assay limit of detection for
RIA of PbTx-3 was about 0.5 ng/mL.
LC/MS analyses. Adduct formation was
analyzed using a Shimadzu VP HPLC system
equipped with a Hypersil Beta-Basic C-18
column (1 × 50 mm, 3 µm; Thermo Electron
Co., San Jose, CA, USA). The mobile phase
consisted of water (A) and methanol (B) in a
binary system, with 0.18% formic acid as an
additive. The elution gradient was 45–75% B
for 30 min, and the ﬂow rate was 0.l mL/min.
We analyzed adduct formation using the Q-
STAR quadropole/time-of-flight mass spec-
trometer (Applied Biosystems/MDS SCIEX,
Foster City, CA, USA). The mass spectrome-
ter detected positive ions over the mass range
m/z 300–1,400 or 100–1,400 atomic mass
units (amu) at an orifice potential of 30 V.
Selective molecular ions of nucleoside modi-
ﬁed with brevetoxin, the molecular ions aris-
ing from the elimination of the ribose moiety
from the parent compounds, and the loss of
respective nucleobase were monitored. Ultra-
violet chromatograms were also recorded at a
wavelength of 260 nm.
Results
Semisynthesis of PbTx-6 nucleoside adducts.
RIA of PbTx-6 extracted from the incubation
mixture with nucleosides identified a reduc-
tion in recovered brevetoxin immuno-
reactivity, consistent with the formation of
brevetoxin nucleoside adducts (Figure 2).
Figure 3A–C shows the LC/MS peak of
nucleoside adducts that were not observed in
control mixtures. Only a single peak of breve-
toxin adduct was identiﬁed with each of these
nucleosides. The molecular ion of each adduct
indicated that one molecule of PbTx-6 was
adducted to each nucleoside. Peaks had
molecular ions corresponding to adduction
products between PbTx-6 and nucleosides:
retained at 11.8 min (m/z 1,154) for breve-
toxin–cytidine (Figure 3A) and at about
15 min (m/z 1,194) for brevetoxin–guanosine
adduct (Figure 3B). Unbound PbTx-6 (m/z
911) was retained at about 18.5 min, identical
for both control and treatments (Figure 3C).
Fragmentation of nucleoside adducts resulted
in initial elimination of the ribose moiety from
the parent compounds: m/z 1,154 to m/z
1,022 for brevetoxin–cytidine and m/z 1,194
to m/z 1,062 for brevetoxin–guanosine. The
loss of respective nucleobase was monitored in
both adducts giving rise to ions m/z 112 or
m/z 152 for cytosine or guanine, respectively.
Fragments of nucleobase imine were seen as
m/z 124 (C=N4–) and m/z 164 (C=N2–) for
cytosine or guanine, respectively. PbTx-6 was
characterized by its daughter fragments m/z
857 and m/z 473 (Figure 3C).
Adduct formation after in vitro exposure.
Lung cells exposed to PbTx-2 showed an
approximate 4-fold increase in the amount
of adduct compared to PbTx-6 treatment.
RIA showed 115.5 ± 31 pg PbTx-6 equiva-
lents per microgram DNA for cells exposed
to PbTx-2 and 34.1 ± 3 pg/µg DNA of cells
exposed to PbTx-6. LC/MS analysis of
extracts of PbTx-2 exposure revealed molec-
ular ions corresponding to products between
brevetoxin and cytidine. These ions included
m/z 1,022 (brevetoxin-nucleobase after los-
ing the sugar moiety) and cytosine m/z 112
and cytosine N 4 imine m/z 124 (Figure 4).
Neither adduct parent molecule nor its legit-
imate sugar-free ion fragment was detected
in PbTx-6 exposures.
Adduct formation after in vivo exposure. A
considerable amount of brevetoxin activity was
retained in lung tissue 24 hr after exposure. An
average of 136.3 ng PbTx-3 equivalents/g of
lung tissue was measured for PbTx-2, while
almost 2-fold more was measured in PbTx-6–
exposed rats. RIA analyses of the nucleic acid
hydrolysate showed about 4-fold greater adduct
formation caused by PbTx-2 exposure
(Figure 5). Further LC/MS analysis of the
Brevetoxin–nucleic acid adduction in rat lung
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Figure 4. LC/MS of brevetoxin–nucleic acid adducts formed by reaction of PbTx-2 with isolated rat lung
cells shown as extracted ion current (m/z 860–1,400) from (A) a total ion chromatogram, (B) mass spectra,
and (C) product ion spectra. Rel Int, relative intensity. The spectra shows brevetoxin–cytidine adduct mol-
ecule (m/z 1,154) and products (m/z 1,022, m/z 124, and m/z 112) resulting from fragmentation of the nucleo-
side. The brevetoxin adduct fragment pattern shown depicts a hypothetical nucleoside linkage to the
epoxide to illustrate potential nucleoside fragmentation. 
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Figure 5. RIA of brevetoxin activity retained in lung
tissues or associated with DNA extracts 24 hr after
in vivo exposures to PbTx-2 or PbTx-6. Data shown
are mean ± SD of PbTx-3 equivalents. 
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PbTx-6nucleic acid hydrosylate of PbTx-2–exposed
lung revealed three molecular ions correspond-
ing to brevetoxin adducts with nucleosides. The
brevetoxin–guanosine adduct retained around
16 min (m/z 1,194) (Figure 6A), brevetoxin–
adenine (m/z 1,046) retained at about 14 min
(Figure 6B), and the brevetoxin–adenosine
adduct retained at about 10.7 min (m/z 1,178;
Figure 6C). Fragmentation spectra of nucleo-
sidic adducts showed initial elimination of the
sugar moiety to give daughter compounds: m/z
1,194 to m/z 1,062 for brevetoxin–guanosine
and m/z 1,178 to m/z 1,042 for brevetoxin–
guanosine. The loss of respective nucleobase
was monitored in both adducts giving rise to
ions m/z 152 or m/z 136 for guanine or ade-
nine, respectively. Fragments of nucleobase
imine were seen as m/z 164 (C=N2–) and m/z
148 (C=N6–). We could not detect adduct for-
mation in hydrolysate extracts from PbTx-6
exposures using similar LC/MS conditions.
Discussion
Brevetoxin, the red tide toxin, is well charac-
terized for its neurotoxic toxic effects mediated
by the voltage-gated sodium channel that are
manifest in NSP (Ramsdell 2008). Respiratory
exposure to seawater aerosols containing
brevetoxins leads to a different constellation of
effects (Backer et al. 2005), some which are
consistent with activation of voltage-gated
sodium channels, whereas others may involve
inﬂammatory reaction pathways (Bossart et al.
1998). Brevetoxins can also lead to potential
genotoxic effects. In vitro studies with human
lymphocytes indicated that brevetoxins cause
single-stranded and and double-stranded
DNA breaks (Sayer et al. 2005), and a follow-
up study in Chinese hamster ovary cells
reported that brevetoxin causes chromosomal
aberrations (Sayer et al. 2006).
Systemic absorption of brevetoxins by
mammals leads to rapid metabolism to produce
more readily excreted polar products (Radwan
et al. 2005). The initial, or phase I reactions of
brevetoxin include oxidation, reduction,
hydrolysis, and epoxidation (Radwan and
Ramsdell 2006). Epoxidation of the H-ring of
brevetoxin B leads to a series of reactive inter-
mediates that are capable of covalently binding
with DNA or causing oxidative DNA damage.
Formation of reactive intermediates is an initial
step in the carcinogenic mechanisms of other
well-known natural toxins such as aflatoxin
(Groopman et al. 2005). In the present study
we examined the subsequent step in this pro-
gression—namely, the formation of breve-
toxin–nucleoside adducts in lung after
intratracheal exposure to brevetoxins. Adduct
formation is a key step in inducing genotoxicity
as a result of exposure to nucleic acid-damaging
chemicals and metabolites.
Mechanism for brevetoxin–DNA adduct
formation. We focused on brevetoxin B
Radwan and Ramsdell
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Figure 6. LC/MS of brevetoxin–nucleic acid adducts formed by brevetoxin
reaction in rat lung after intratracheal exposure. Rel Int, relative intensity.
(A–C) Extracted ion current (m/z 860–1,400) from total ion chromatograms,
mass spectra, and product ion spectra for (A) brevetoxin–guanosine m/z
1,194, (B) brevetoxin–adenine m/z 1046, and (C) brevetoxin–adenosine m/z
1,178, respectively. The brevetoxin adduct fragment patterns shown in the
spectra of (A–C) depict a hypothetical nucleoside linkage to the epoxide to
illustrate potential nucleoside or nucleotide fragmentation. analogs; however, similar processes can be
expected for brevetoxin A analogs. The initial
brevetoxin B produced by the algae has a reac-
tive α,β-unsaturated aldehyde extending from
the terminal K-ring and has been designated as
PbTx-2. PbTx-2 is also subject to epoxidation,
in the 27, 28 position of the H-ring designated
PbTx-6, which as been found both in algal cells
(Chou et al. 1985) and as a metabolic product
of PbTx-2 in liver cells (Radwan and Ramsdell
2006). In this article, we first described the
semisynthesis of brevetoxin–nucleic acid
adducts produced from reactions of PbTx-6
with cytosine and guanosine. Reaction of
PbTx-6 with nucleosides was noted by a
decrease in toxin activity in the assay mixture
compared to the control, which suggests that
nucleosidic adducts may have a lower afﬁnity
for brevetoxin antibody. LC/MS data provided
structural evidence for the formation of cova-
lent brevetoxin–cytidine and brevetoxin–
guanosine adducts. The MS/MS spectrum of
each adduct was identified by a parent [M +
PbTx-6+H]+ ion, and two major fragment ions:
[M + PbTx-6 – 132+H], probably formed by
elimination of sugar moiety, and [M + PbTx-6
– 132 – 18+H], likely due to further loss of
water. Elimination of respective nucleobase
was observed as m/z 112 and m/z 152 for
brevetoxin–cytidine and brevetoxin–guanosine,
respectively. Respective nucleobase imine frag-
ments m/z 124 and m/z 164 were also observed,
indicating that adduction sites of nucleobases
toward brevetoxin occurs at least in part on the
exocyclic NH2 groups of the base moieties.
LC/MS analysis did not yield sufﬁcient struc-
tural information to conﬁrm the site of nucleo-
side linkage to the H-ring epoxide.
Characterization of brevetoxin–nucleoside
adducts. Brevetoxin–nucleoside adducts were
examined after in vitro exposure of brevetoxins
to lung ﬁbroblasts and after in vivo exposure
of rats to brevetoxins via intratracheal
administration. Two brevetoxin congeners
were chosen for exposure, PbTx-6, which has
the H-ring epoxide, and PbTx-2, which has
been found to be metabolized to form the
H-ring epoxide in liver cells. Both brevetoxin
congeners yielded brevetoxin immunoreactiv-
ity to puriﬁed nucleoside fractions recovered
from exposed lung cells and lung tissue; how-
ever, in each case PbTx-2 yielded four times
the activity found with PbTx-6 treatment.
Extracted ion chromatograms identiﬁed breve-
toxin adducts only with PbTx-2 treatment.
Brevetoxin–cytidine adducts were detected in
PbTx-2–exposed lung cells, but no adducts
were found in the nucleic acid extracts of lung
cells exposed to PbTx-6 under the same
LC/MS conditions. Adducts of brevetoxin–
guanosine (m/z 1,194) and brevetoxin–
adenosine (m/z 1,178) were identiﬁed in the
lung of rats exposed to PbTx-2 but not
PbTx-6. These results are the ﬁrst to establish
the in vitro and in vivo formation of nucleic
acid adducts after brevetoxin exposure.
Although the reactivity of PbTx-2, and
not its epoxide PbTx-6, might be taken to
mean that the epoxide is not the likely reactive
group for conjugation with the nucleoside,
further interpretation may indicate otherwise.
PbTx-6 also has the K-ring α,β-unsaturated
aldehyde, indicating that it should be as reac-
tive for nucleoside conjugation by Michael
addition as PbTx-2, which it is not. This sug-
gests that epoxidation may be an intermediate
step for PbTx-2 adduction. Epoxides are very
aggressive alkylating agents of nucleophilic
sites of nucleosides, and epoxides formed
metabolically may have a higher probability of
binding to DNA. Hence, an epoxide formed
intracellularly by metabolism of PbTx-2
would have greater access to DNA than the
epoxide of PbTx-6 when administered into
the animal. DNA adduction to a metabolically
formed epoxide of brevetoxin is also consistent
with the report that both the single and dou-
ble reduction of α,β-unsaturated aldehyde
derivates of PbTx-2 caused DNA breaks in
human lymphocytes as effectively as PbTx-2
(Sayer et al. 2005). Adduction of guanosine or
adenosine to the epoxide would lead to the
brevetoxin–guanosine and brevetoxin–
adenosine masses m/z 1,194 and 1,178, respec-
tively, identiﬁed in lung nucleic acid hydrolytes.
However the K-ring R group α,β-unsaturated
aldehyde is also likely to react with the nucleo-
side. For example, Michael addition with the
nucleoside and subsequent oxidation of the
aldehyde to carboxylic acid would also lead to
the same mass adduct products. Additional
analysis will be necessary to provide full struc-
tural assignments of the brevetoxin–nucleoside
adducts in lung tissues. The structural assign-
ment of the toxin nucleoside linkage, however,
is less critical from a functional perspective, as
multiple reaction products are bound to result
from brevetoxin reactive intermediates. It is
likely that more sensitive LC/MS techniques
will identify additional brevetoxin–nucleic
acid and brevetoxin–protein adducts in lung.
This is important because, even though major
toxin nucleic acid adducts product are neces-
sary for the development of markers of expo-
sure, less prominent adduct products are often
responsible for genotoxic effects (Groopman
et al. 2005).
Potential for genotoxic effects following red
tide exposure. This study presents the ﬁrst evi-
dence that brevetoxins form nucleoside adducts
in lung tissue. We identified brevetoxin–
guanosine (m/z 1,194) and brevetoxin–
adenosine (m/z 1,178) as major products of
hydrolyzed lung DNA after intratracheal
exposure of rats. The finding of brevetoxin
conjugated to guanosine and adenosine after
hydrolysis of lung DNA is consistent with
brevetoxin metabolism resulting in a reactive
intermediate capable of reaching the nucleus
from its site of metabolism in the mito-
chondria to react with DNA purines. DNA
purine adducts are known to be unstable and
to undergo depurination. The release of the
nucleotide base adduct is an indication of a
promutagenic lesion. Structurally, the lesion
in the DNA is the result of an apurinic site
that remains in the DNA base sequence. The
identification of brevetoxin–nucleotide base
(adenine) adduct (m/z 1,046) in addition to
brevetoxin–nucleoside (adenosine) adduct
(m/z 1,178) in rat lung tissue is consistent
with the formation of promutagenic lesions
after brevetoxin exposure. Promutagenic
lesions resulting from depurination of afla-
toxin–nucleoside adducts are susceptible to
faulty repair, causing G to T transversions,
which have been shown to result in inactiva-
tion of the TP53 tumor-suppressor gene in
aﬂatoxin-associated hepatocarcinoma (Kensler
et al. 2003).
Potential risk of exposure to brevetoxin
aerosols. The risk of brevetoxin adduct forma-
tion and resultant depurination is not known.
Individuals are continually exposed to envi-
ronmental agents capable of direct adduct for-
mation as well as adduct formation through
environmental agents that induce oxidative
damage. It is possible that exposure to breve-
toxins in aerosols, like other inhaled environ-
mental genotoxic carcinogens, including
polyacromatic hydrocarbons (Schoket 1999)
and tobacco smoke (Wiencke 2002), add to
the baseline levels of DNA adducts. Baseline
levels of adducts in humans are estimated to
be in the range of 0.1–1.0 adduct per 108
unmodiﬁed DNA bases, and this burden can
rise by four orders of magnitude in animals
exposed to carcinogenic levels of genotoxic
agents (Singh and Farmer 2006). A question
that remains is whether inhalation exposure
to brevetoxin aerosols leads to signiﬁcant lung
DNA depurination. Key to this question is
the rate of brevetoxin adduction to DNA
bases in lung and the extent of exposure.
The identification of brevetoxin–purine
adducts now provides a foundation for biolog-
ical monitoring of human exposure to such
genotoxic environmental agents. The dose lev-
els used in these in vitro and in vivo experi-
ments were not meant to be reflective of
human inhalation exposure to brevetoxins,
which has been estimated at 3 and 20 ng/hr
for red tide events in Florida (2003) and Texas
(2000), respectively (Cheng et al. 2005; Pierce
et al. 2005). Rather, the dosage was high, by
several orders of magnitude, to optimize the
search for toxin–nucleoside adducts. Dose–
response studies are an important next step,
and previous studies have shown that DNA
adducts are formed on a linear basis to dose
(Buss et al. 1990). However, most biological
monitoring studies use readily obtained
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adducts, serum for albumin adducts or urine
for nucleotide adducts. The release of the
nucleotide adduct from target tissue DNA as a
result of depurination leads to the adduct
elimination in urine. Identiﬁcation of urinary
nucleotide adducts using LC/MS has provided
a foundation for large-scale monitoring studies
of several genotoxic agents (Shuker and
Farmer 1992; Singh and Farmer 2006) and
could prove useful for brevetoxins as well.
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